FDA Issues Warning Letter to Bell-More Laboratories - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Issues Warning Letter to Bell-More Laboratories


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Rockville, MD (Jan. 5)—The US Food and Drug Administration (www.fda.gov) issued a Warning Letter to Bell-More Laboratories (Hampstead, MD, www.bell-more.com) following the agency’s August 2006 inspection of the company’s Hampstead pharmaceutical facility. During the inspection, the agency documented deviations from CGMP regulations in 21 CFR Parts 210 and 211 that caused Bell-More’s finished products to be adulterated. The agency asserted that Bell-More’s inadequate controls and documentation create the potential for the migration of potent compounds throughout the facility.

The deviations enumerated in the letter include the failure to establish defined areas or other control systems to prevent contamination or mixups for handling and manufacturing potent compounds; the failure to keep records for the maintenance, cleaning, and sanitizing of equipment; the failure to adequately validate cleaning procedures for manufacturing and packaging equipment; the failure to establish and follow procedures to prevent microbiological contamination; the failure to establish procedures to ensure drug identity, strength, quality, and purity; and the failure to establish testing procedures for finished product.

Bell-More Laboratories is a contract pharmaceutical manufacturer specializing in the custom lyophilization of small-volume parenteral drugs in vials and syringes. For the full text of the Warning Letter, click here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here